Introduction: Many factors concomitantly influence the quality of life of patients with schizophrenia in a long-stay psychiatric facility. Th e appropriate selection of antipsychotics and the intensity of their adverse effects exert a significant influence on the quality of life of these patients. Th e aim of this study was to identify the influence of antipsychotic-related factors on the quality of life of patients with schizophrenia.
Methods: Th e study included 102 beneficiaries at the Institute for Accommodation of Adults “Male Pčelice” in Kragujevac. Th e patients were interviewed on in one day using the questionnaire issued by the World Health Organization. The specified data were obtained from the health files of the beneficiaries. We performed a comparison between patients receiving only atypical antipsychotics, typical antipsychotics or a combination thereof.
Results: Th e patients who were receiving only atypical antipsychotics demonstrated better physical health quality of life scores in comparison to those who received combined antipsychotics (77.14 vs. 68.57; U = 332.0; p = 0.02). A statistically significant difference in the mental health quality of life domain was observed between groups of patients receiving various antipsychotic treatments (31.96 vs. 55.27 vs. 49.46; c2 = 7.02; p = 0.03).
Conclusion: Patients in a long-stay psychiatric facility who received atypical antipsychotics demonstrated a better quality of life in comparison to those who received typical antipsychotics, possibly due to the superior safety profile of atypical antipsychotics and a greater feeling of individual contentment.
1. Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ.Hospital and community-based care for patients with chronic schizophrenia in Hong Kong- quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 2003; 38(4): 196-203.
2. Salome F, Petitjean F, Germain C, Demant JC. The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients’ expectations.
A comparative study. Encephale 2004; 30(1): 60-8.
3. Rossler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C.Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand. 1999; 100(2): 142-8.
4. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010; 26(4): 787-801.
5. Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2): 109-19.
6. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia.Acta Psychiatr Scand Suppl. 2009; 438: 22-8.
8. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L. The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. Qual Life Res. 2011; 20(7): 1079-89.
9. World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Genova: WHO, 1993.
10. Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med. 2009; 87(9): 593-8.
11. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71(1): 137-44.
12. Midori Fujikawa, Takashi Togo, Asuka Yoshimi et al Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro Psychopharmacology & Biological Psychiatry 2008; 32: 755-760.
13. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719-23.
14. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A,Wagner T, et al Prediction of remission as a combination of symptomatic and functionalremission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-7.
15. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry 2002; 159: 103-8.
16. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S et al The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psichiatry 2003; 18(5): 432-40.
17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt- LASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
18. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-12.
19. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW.Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-60.